In the BioHarmony Drug Report Database
Nusinersen
Spinraza (nusinersen) is an oligonucleotide pharmaceutical. Nusinersen was first approved as Spinraza on 2016-12-23. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy. Spinraza’s patents are valid until 2035-09-11 (FDA).
Trade Name
|
Spinraza |
---|---|
Common Name
|
nusinersen |
ChEMBL ID
|
CHEMBL3301572 |
Indication
|
spinal muscular atrophy |
Drug Class
|
Antisense oligonucleotides |
Image (chem structure or protein)